載入中
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
前收盤價
US$12.01
+US$0.03 · +0.25%
盤前
US$11.81
−US$0.20 · -1.67%
10月8日 上午8:42 ET
盤中時間採用ET。市場資料可能有所延遲。
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
日內區間
目前US$12.01
52週區間
目前US$12.01
盤中時間採用ET。市場資料可能有所延遲。
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
日內區間
目前US$12.01
52週區間
目前US$12.01
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 122萬 USD | 110.7萬 USD | 103.2萬 USD | — | — |
| 毛利 | −122萬 USD | −110.7萬 USD | −103.2萬 USD | — | — |
| 研究與開發 | 1.1億 USD | 1.14億 USD | 8517.2萬 USD | 6168萬 USD | 5685.8萬 USD |
| 銷售、一般及管理費用 | 3318.6萬 USD | 2882.3萬 USD | 2560.8萬 USD | 2508.7萬 USD | 2201.3萬 USD |
| 營業費用 | 1.42億 USD | 1.42億 USD | 1.1億 USD | 9176.7萬 USD | 7887.1萬 USD |
| 利息收入 | — | — | 1008.3萬 USD | 264.5萬 USD | 14.1萬 USD |
| 利息支出 | — | — | — | 264.5萬 USD | — |
| 折舊和攤銷 | 122萬 USD | 110.7萬 USD | 103.2萬 USD | 96.6萬 USD | 89.7萬 USD |
| 營業利益 | −1.43億 USD | −1.43億 USD | −1.11億 USD | −9176.7萬 USD | −7887.1萬 USD |
| 淨利 | −1.29億 USD | −1.28億 USD | −1.01億 USD | −8912.2萬 USD | −7871.5萬 USD |
公司資料更新於 2026年10月8日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$23.50
上漲空間 95.67%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3847.6萬0.00%2.3兆 USD0.03%US$381.03-0.40%
State Street SPDR S&P Biotech ETFXBI3033.78萬0.29%100.75億 USD0.35%US$150.23-0.44%
iShares Russell 2000 ETFIWM2339.42萬0.03%785.63億 USD0.19%US$277.7-1.29%
Vanguard Extended Market ETFVXF1238.31萬0.01%954億 USD0.05%US$233.49-1.56%
Dimensional - US Small Cap ETFDFAS884.32萬0.03%336.6億 USD0.31%US$77.92-1.38%
iShares Biotechnology ETFIBB618.06萬0.06%104.01億 USD0.44%US$203.34+0.12%
Schwab U.S. Small-Cap ETFSCHA565.74萬0.03%216.99億 USD0.03%US$32.61-1.47%
Vanguard Russell 2000 ETFVTWO557.7萬0.03%180億 USD0.06%US$112.21-1.26%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
